HMGCR and psoriasis: Sensitivity analysis revealed no evidence of heterogeneity or horizontal pleiotropy.<h4>Conclusion</h4>This study revealed the existing HMGCR inhibitors (stains) might be protective for reducing nonmelanoma skin cancer risk, and HMGCR inhibitors (stains) and PCSK9 inhibitor (alirocumab) might be promising for reducing psoriasis risk in the European population.